טוען...
Quizartinib (AC220): a promising option for acute myeloid leukemia
Quizartinib is an effective therapy for patients with FLT3-ITD acute myeloid leukemia (AML) by continuing to inhibit the activity of FLT3 gene, leading to apoptosis of tumor cells. Multiple clinical trials have proved that it is effective in relapsed or refractory AML with an FLT3-ITD mutation. In t...
שמור ב:
| הוצא לאור ב: | Drug Des Devel Ther |
|---|---|
| Main Authors: | , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Dove
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6497874/ https://ncbi.nlm.nih.gov/pubmed/31114157 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S198950 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|